Tue, Sep 16, 2014, 6:24 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Isis Pharmaceuticals, Inc. Message Board

  • zba5552003 zba5552003 Mar 12, 2013 5:35 AM Flag

    News overdue!

    ISIS Pharmaceuticals, Inc. (ISIS) Update On Its Metabolic Franchise Conference Call December 7, 2012
    Isis-FGFR4: three month ago
    Stan Crookje "It is a very complicated study because we are looking at normal volunteers and trying to measure a variety of, particularly, FGF19, which is a difficult to measure substance. So the study has actually completed but the data analysis is taking quite a long time. Just to get all the information procedures, specialized assays. So it will be a little while. I could have just said, it will be a little while.

    ISIS-CRPRx JPM Conference/09. January 2013
    Endotoxin Challenge Study in ~30 Healthy Volunteers (Completed)
    Study designed to demonstrate that ISIS-CRPRx can blunt acute severe
    increases in CRP
    Exploring other key inflammatory mediators such as TNF-α, IL-1β, IL-6
    and complement
    Data planned for 1H 2013

    Severely Elevated Triglyceride Study, ~100 Patients with Triglycerides between 440-2000
    mg/dL (Ongoing) 09.01.2013
    Study designed to demonstrate that ISIS-APOCIIIRx can decrease triglycerides and apoC-III in
    patients with severely elevated triglycerides
    Doses: 100, 200, or 300 mg/wk
    Data planned for mid 2013

    Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia/ 04. May 2012

    8 weeks: Screening & Diet Run-in
    13 weeks: Treatment Period
    12 weeks: Post-Treatment #$%$ Period
    = 8 month --- completed about end of January 2013

39.50+0.66(+1.70%)Sep 16 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.